vimarsana.com

Page 52 - ஹைதராபாத் அடிப்படையிலானது பாரத் பயோடெக் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Telangana Free Vaccination Drive: Bharat Biotech Asked to Prioritise TS in Vaccine Supply

Apr 28, 2021, 08:44 IST Hyderabad-based Bharat Biotech is all ready to increase the production of its indigenously developed Covaxin to 12 million doses a month by July. Currently, the company is producing only 5 million. This decision was taken by the company to provide a boost to India’s Covid-19 inoculation programme amid the second wave of dangerous coronavirus infection. The Telangana state government has requested Bharat Biotech to give priority to the state and ensure the supply of maximum doses of coronavirus vaccine. Recently, Telangana Chief Minister K Chandrashekar Rao announced that they are going to give free vaccination to all the people above 18 years of age. 

Covaxin found to neutralise the India variant, says Fauci

Covaxin found to neutralise the India variant, says Fauci ​ By IANS | ​ 11 Views Anthony Fauci. Image Source: IANS News Washington, April 28 : The made-in India Covaxin vaccine, developed by Hyderabad-based Bharat Biotech, can neutralise the B1617 variant of coronavirus, said White House s chief medical adviser Dr. Anthony Fauci. Now, this is something we are still gaining data on, but most recent data looking at convalescent sera of Covid-19 cases in people who received Covaxin, it was found to neutralise the 617 variant, Fauci was quoted as saying during the White House press briefing. Fauci, who is US President Joe Biden s chief adviser on the Covid pandemic, quoted the recent Phase 3 clinical trials of Covaxin by ICMR, which claimed that the vaccine neutralises multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain (B1617) as well. He called vaccination an important antidote .

Welcome To IANS Live - NATION - Covaxin found to neutralise the India variant, says Fauci

Photo Credit: IANS IANSLive Washington, April 28 (IANS) The made-in India Covaxin vaccine, developed by Hyderabad-based Bharat Biotech, can neutralise the B1617 variant of coronavirus, said White House s chief medical adviser Dr. Anthony Fauci. To get full access of the story, click here to subscribe to IANS News Service © 2021 IANS India Private Limited. All Rights Reserved. The reproduction of the story/photograph in any form will be liable for legal action. For news, views and gossips, follow IANS at Twitter. Update: 28-April-2021

Serum Institute reduces price of its COVID-19 vaccine Covishield to Rs 300 per dose to states: CEO Adar Poonawalla

: Wednesday, April 28, 2021, 5:56 PM IST Serum Institute reduces price of its COVID-19 vaccine Covishield to Rs 300 per dose to states: CEO Adar Poonawalla Serum Institute reduces price of its COVID-19 vaccine Covishield to Rs 300 per dose to states: CEO Adar Poonawalla The Serum Institute of India (SII) has reduced the price of its COVID-19 vaccine Covishield from Rs. 400 to Rs. 300 per dose to the states, said CEO Adar Poonawalla on Wednesday. As a philanthropic gesture on behalf of @SerumInstIndia, I hereby reduce the price to the states from Rs.400 to Rs.300 per dose, effective immediately; this will save thousands of crores of state funds going forward. This will enable more vaccinations and save countless lives, Poonawalla tweeted.

Maharashtra decides to vaccinate 18 to 44 age group people free of cost

Maharashtra decides to vaccinate 18 to 44 age group people free of cost Mirror Online / Updated: Apr 28, 2021, 16:23 IST Representational image. Maharashtra government on Wednesday decided to vaccinate people between the age of 18 to 44 for free of cost. The decision comes amid such a situation where the state is facing a shortage of COVID-19 vaccines and even as many people above the age of 44 are yet to receive a second dose. To vaccinate people between 18-44, the state will need 12 crore vaccine doses. Meanwhile, Health Minister Rajesh Tope informed that vaccination will not start on May 1. Tope said that they are willing to conduct vaccination, but they can t start due to the unavailability of vaccine doses.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.